Elevated urinary transforming growth factor β1 level as a tumour marker and predictor of poor survival in cirrhotic hepatocellular carcinoma
1997

Urinary TGF-β1 as a Tumor Marker in Liver Cancer

Sample size: 238 publication Evidence: moderate

Author Information

Author(s): JF Tsai, JE Jeng, LY Chuang, ML Yang, MS Ho, WY Chang, MY Hsieh, ZY Lin, JH Tsai

Primary Institution: Kaohsiung Medical College, Taiwan

Hypothesis

Elevated urinary TGF-β1 levels can serve as a tumor marker and predictor of poor survival in patients with cirrhotic hepatocellular carcinoma.

Conclusion

Elevated urinary TGF-β1 levels are associated with poor survival in patients with cirrhotic hepatocellular carcinoma.

Supporting Evidence

  • TGF-β1 levels in HCC patients were significantly higher than in cirrhosis alone or healthy controls (P = 0.0001).
  • An inverse correlation was found between TGF-β1 and AFP levels (r = -0.292, P = 0.004).
  • Median survival in HCC patients with raised TGF-β1 was shorter than those with normal levels (P = 0.018).
  • TGF-β1 levels decreased after complete treatment with transcatheter arterial chemoembolization (P = 0.0001).
  • Multivariate analysis indicated that TGF-β1 and AFP were significantly correlated with the presence of HCC.

Takeaway

This study found that higher levels of a substance called TGF-β1 in urine can help doctors tell if someone has a serious liver cancer and how well they might do.

Methodology

Urinary TGF-β1 and serum AFP levels were measured in patients with cirrhotic HCC, cirrhosis alone, and healthy controls.

Limitations

The study did not determine plasma TGF-β1 levels and relied on urinary samples.

Participant Demographics

94 patients with cirrhotic HCC, 94 age- and sex-matched patients with cirrhosis alone, and 50 healthy adults.

Statistical Information

P-Value

0.0001

Confidence Interval

95% CI 128-210 days

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication